

Minireview

Far-infrared therapy for cardiovascular, autoimmune, and other chronic health problems: A systematic review

Shanshan Shui^{1,2}, Xia Wang¹, John Y Chiang^{3,4} and Lei Zheng^{1,2}

¹School of Medical Engineering, Hefei University of Technology, Hefei 230009, China; ²School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei 230009, China; ³Department of Computer Science & Engineering, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan; ⁴Department of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

Corresponding authors: Lei Zheng. Email: lzhenh@hfut.edu.cn; John Y Chiang. Email: chiang@cse.nsysu.edu.tw

Abstract

Physical therapy (physiotherapy), a complementary and alternative medicine therapy, has been widely applied in diagnosing and treating various diseases and defects. Increasing evidence suggests that convenient and non-invasive far-infrared (FIR) rays, a vital type of physiotherapy, improve the health of patients with cardiovascular disease, diabetes mellitus, and chronic kidney disease. Nevertheless, the molecular mechanisms by which FIR functions remain elusive. Hence, the purpose of this study was to review and summarize the results of previous investigations and to elaborate on the molecular mechanisms of FIR therapy in various types of disease. In conclusion, FIR therapy may be closely related to the increased expression of endothelial nitric oxide synthase as well as nitric oxide production and may modulate the profiles of some circulating miRNAs; thus, it may be a beneficial complement to treatments for some chronic diseases that yields no adverse effects.

Keywords: Physical therapy, far-infrared (FIR), cardiovascular disease (CVD), diabetes mellitus (DM), miRNA

Experimental Biology and Medicine 2011; 0: 1–9. DOI: 10.1177/1535370215573391

Introduction

Infrared radiation is an invisible form of electromagnetic energy, the wavelength of which is longer than that of visible light. Infrared radiation can be categorized into three groups according to wavelength, namely near infrared (NIR, 0.8–1.5 μm), middle infrared (MIR, 1.5–5.6 μm), and far infrared (FIR, 5.6–1000 μm).¹ Infrared radiation probably enables multiple forms of energy to be transferred into subcutaneous tissue (approximately 2–3 cm deep) without stimulation or excessive heating.² In one study, skin temperature increased to 38–39°C after FIR treatment for 30 min to 1 h with 20 cm of spacing between ceramic plates and the skin.³ Thus, FIR therapy may yield none of the side effects of traditional thermal therapy, such as infection or burn injury, and has therefore been widely employed to promote health.

FIR treatment methods can be divided into two categories according to clinical implementation in general. In the first category, an FIR emitter composed of electrified ceramic plates is placed 20 cm above a patient and provides low energy to increase skin temperature steadily.³ In addition, the FIR radiator is frequently used in experiments for local (or point) treatment by maintaining the surface temperature lower than 40°C. In the other more prevalent

category, FIR dry sauna therapy,⁴ light is employed to create heat by using a sauna. Unlike traditional saunas, which apply heat to warm the body by increasing the ambient air temperature, FIR saunas heat the body directly without employing the air as a heat transfer medium.⁵ In a previous study, sauna therapy was performed using an FIR dry sauna device at 60°C for 15 min, followed by traditional warm keeping for 30 min.⁶

Although previous studies have shown that FIR radiation produces thermal and non-thermal effects, such as increasing artery blood flow⁷ and peripheral blood circulation,⁸ improving endothelial function,⁹ alleviating fatigue¹⁰ and pain,¹¹ reducing blood pressure,¹² and promoting capillary dilatation,¹³ the precise mechanism has yet to be thoroughly understood. Therefore, the purposes of this study were to review and summarize published data on FIR therapy on different types of diseases (Table 1) and to delineate the mechanisms of FIR therapy.

FIR therapy for cardiovascular disease

Cardiovascular disease

Cardiovascular disease (CVD), the leading cause of deaths worldwide, refers to any disease affecting the

Table 1 Studies relevant to far-infrared rays

Disease	Subjects	Exposure type	Duration	Primary parameters	Reference
CVD	Human	FIR sauna	2 weeks	FMD	16
CVD	Human	FIR sauna	2 weeks	8-epi-prostaglandin F _{2α} , Systolic blood pressure	28
CHF	Hamster	FIR sauna	4 weeks	eNOS mRNA and protein NO production	24
CHF	Human	FIR sauna	3 weeks	FMD 6MWD	17
DM	Human	Local FIR stimulation	2 weeks	8-epi-prostaglandin F _{2α}	43
DM	Human	Local FIR stimulation	4 weeks	Cortisol Blood glucose Insulin	47
DM	Mouse	FIR sauna	5 weeks	Blood flow EPC mobilization and differentiation Oxidative stress	48
ESRD	Human	Local FIR stimulation	1 years	Qa AVF unassisted patency Incidence of AVF malfunction	55
CKD	Human	Local FIR stimulation	1 years	AVF PTA-unassisted patency AVG PTA-unassisted patency	59
CKD	Human	Local FIR stimulation	1 years	Rate of AVF maturation AVF unassisted patency	61
Hindlimb ischemia	Mouse	FIR sauna	5 weeks	Blood flow Capillary density eNOS expression NO production	7
PAD	Human	FIR sauna	10 weeks	Pain score Blood flow 6MWD	4
Testis ischemia	Rat	Local FIR stimulation	30 min	HO-1 protein Apoptosis of testis tissues	68

FIR: far-infrared; CVD: cardiovascular disease; FMD: flow-mediated endothelium-dependent dilation; CHF: chronic heart failure; eNOS: endothelial nitric oxide synthase; NO: nitric oxide; 6MWD, 6-min walk distance; DM: diabetes mellitus; EPC: endothelial progenitor cell; ESRD: end-stage renal disease; Qa: access flow; AVF: arteriovenous fistula; CKD: chronic kidney disease; AVG: arteriovenous graft; PTA: percutaneous transluminal angioplasties; PAD: peripheral arterial disease; HO-1: heme oxygenase-1.

cardiovascular system including cerebral and renal vascular diseases, cardiac disease, and peripheral arterial disease.¹⁴ The most common factors that induce CVD are atherosclerosis and hypertension. Moreover, even in healthy asymptomatic elderly people, various alterations in physiology and morphology affect cardiovascular function and thus result in an increased risk of CVD,¹⁵ thus, determining treatments for curing the disease is imperative.

Effects of FIR on CVD

Evidence has indicated that FIR rays exert protective effects on CVD. Several weeks of sauna therapy markedly enhanced flow-mediated endothelium-dependent dilation of the brachial artery ($P < 0.001$),^{16–18} which was associated with an increase in cardiopulmonary exercise tolerance.^{17,18} Because endothelial dysfunction is typically observed in patients with hypertension,¹⁹ hypercholesterolemia,²⁰ diabetes mellitus (DM),²¹ and obesity and patients who smoke,²² sauna treatments probably play a therapeutic role for patients with coronary risk factors, suggesting that sauna treatments improve vascular endothelial function.

Compelling evidence has indicated that vascular endothelial function is closely associated with endothelial nitric oxide synthase (eNOS), which catalyzes the amino acid L-arginine into L-citrulline and nitric oxide (NO) in the endothelium. NO is a crucial vasodilator substance, which prevents the progression of atherosclerosis by dilating blood vessels and inhibiting some arterial disorders such as platelet aggregation and the migration and proliferation of smooth muscle cells.²³ Ikeda *et al.* reported that one month of FIR sauna therapy significantly upregulated

eNOS mRNA and protein expression (0.73 ± 0.04 vs. 1.02 ± 0.02 , $P < 0.01$; 3250 ± 70 vs. 4090 ± 60 , $P < 0.01$, respectively) as well as serum NO production (3.98 ± 0.43 mmol/L vs. 4.66 ± 0.5 mmol/L, $P < 0.05$) in cardiomyopathic hamsters with chronic heart failure (CHF).²⁴ In addition to enhancing eNOS expression, FIR increases NO production probably by promoting the Ca²⁺/calmodulin-dependent protein kinase II (CaMKII)-mediated phosphorylation of eNOS at serine 1179 to increase eNOS activity.²⁵ Although FIR radiation can notably increase the temperature of culture media and intracellular Ca²⁺ levels, temperature-sensitive calcium channels and transient receptor potential vanilloid may not contribute to the pathway of the CaMKII-mediated phosphorylation of eNOS.²⁵ Thus, we propose that the non-thermal effects of FIR radiation, as has been recently shown for other types of non-ionizing radiation,²⁶ may be involved in this pathway by activating voltage-gated calcium channels.²⁷ Nevertheless, all of these mechanisms suggested that upregulating NO production by increasing eNOS expression level and its phosphorylation level is a critical manner in which FIR therapy improves endothelial function in patients with CHF.

Notably, urinary 8-epi-prostaglandin F_{2α} (a product of lipid peroxidation) levels were markedly lower in participants with coronary risk factors who received an FIR dry sauna for two weeks compared with those of controls.²⁸ Because 8-epi-prostaglandin F_{2α} is a reliable marker of oxidative stress *in vivo*, and oxidative stress is involved in the development of atherosclerosis and heart failure,²⁹ the results suggested that repeated FIR ray therapy can reduce oxidative stress,³⁰ preventing the progression of

atherosclerosis. Because oxidative stress reduces the bioavailability of NO (free radicals can inactivate NO),³¹ a reduction in oxidative stress probably indicates an improvement in endothelial function through an increase in NO production.

The enhancement in eNOS expression caused by FIR stimulation may be related with miRNA. Shear stress is crucial to increasing eNOS activity by stimulating its expression.³² All of the aforementioned studies have suggested that FIR therapy accelerates peripheral blood flow, leading to an increase in shear stress, followed by increases in eNOS activity and NO production and upregulation of eNOS expression. Consequently, vascular endothelial function and exercise tolerance are improved.

A previous study reported that miRNAs are essential for various CVDs because depletion in the miRNA-processing enzyme engenders defects in cardiac development and angiogenesis.³³ Several studies have revealed that shear stress or FIR can regulate the expression of miRNAs in endothelial cells. For instance, miRNA-21 induced by shear stress in endothelial cells can modulate endothelial cell apoptosis and eNOS activity as well as NO production.³⁴ In one study, miRNA-663 played vital roles in shear stress-induced inflammatory responses by derepressing inflammatory response genes.³⁵ A recent study determined that FIR treatment enhanced the expression of miRNA-31 and miRNA-720, thereby increasing coronary artery disease endothelial progenitor cell (EPC) expression and rescuing the angiogenic and vasculogenic abilities of EPCs both *in vitro* and *in vivo*.³⁶ Circulating miRNAs (e.g. miRNA-1, miRNA-17, miRNA-92a, miRNA-126, miRNA-133, and miRNA-145) in the blood cells or serum/plasma have been identified as potential biomarkers of CVD³⁷ and can be used for diagnosing and determining the prognosis of acute myocardial infarction.³⁸ In summary, we suspect that FIR improves the endothelial function of patients with CVD by increasing eNOS and NO levels by promoting shear stress and altering the expression profiles of some circulating miRNAs.

FIR therapy for DM

Diabetes mellitus

DM is a group of metabolic diseases caused either by a deficiency in insulin production (type 1) or by development of insulin resistance (type 2).³⁹ Most diabetes cases can be grouped into two broad etiopathogenetic categories: type 1 DM, caused by failure of the pancreas to secrete insulin; and type 2 DM, caused by the inability of the body to respond properly (e.g. resistance) to insulin action or insulin secretory response.⁴⁰ A person with DM (type 1 or 2) has high concentrations of blood sugar, which undermine the blood vessels, nerves, kidneys, and other systems of the body.⁴⁰

Effects of FIR on DM

Masuda *et al.* demonstrated that repeated dry sauna therapy by using FIR reduced urinary levels of 8-epi-prostaglandin F_{2α} (an oxidative stress marker)²⁸ and that DM was associated with increased oxidative stress,⁴¹

which has a marked insulin-resistance effect.⁴² Kawaura *et al.* investigated the oxidative-stress-related modulatory effect of FIR local stimulation in bedridden patients with type 2 DM.⁴³ Two weeks of local FIR therapy administered to the legs significantly reduced plasma 8-epi-prostaglandin F_{2α} levels in type 2 DM patients ($P < 0.05$).⁴³ A reduction in eNOS bioactivity was involved in the pathogenesis of oxidative stress in skeletal muscle insulin resistance.⁴⁴ Furthermore, eNOS played a critical role in regulating insulin sensitivity.⁴⁵ Overall, FIR therapy may improve skeletal muscle insulin resistance through eNOS expression following a decrease in oxidative stress in patients with type 2 DM.

Patients with DM sustain stress because of daily dietary restrictions, leading to an excessive release of cortisol, causing diverse negative reactions such as hypertension.⁴⁶ Consequently, DM is exacerbated. Ryotokuji *et al.* indicated that four weeks of FIR radiation administered to the feet of type 2 DM patients significantly reduced cortisol levels and blood glucose levels.⁴⁷ Therefore, assuming that FIR therapy normalizes blood glucose levels by reducing serum levels of cortisol (adrenal glucocorticoid hormones) and thereby improves the ability to respond to insulin action in patients with type 2 DM is reasonable.

Huang *et al.* observed that FIR therapy increased blood flow recovery by 48%, increased bone marrow-derived EPC differentiated into endothelial cells ($11.2 \pm 1.1/\text{HPF}$ vs. $18.8 \pm 2.0/\text{HPF}$, $P < 0.01$), and reduced oxidative stress ($P < 0.05$) in streptozotocine-induced diabetic mice.⁴⁸ Moreover, the benefits of local FIR radiation were abolished after injection with L-NAME (an eNOS inhibitor).⁴⁸ Because neovascularization requires bone-marrow-derived circulating EPCs for vasculogenesis,⁴⁹ high glucose-impaired capacities of EPCs probably involve NO-related mechanisms.⁵⁰ In addition, NO can modify the mobilization and differentiation of EPCs,⁵¹ and an increase in free radicals in tissue ischemia may downregulate NO bioavailability by directly inactivating NO.³¹ Thus, FIR treatment may be related to a NO-related pathway. Moreover, FIR therapy is suggested to have benefits of promoting blood flow recovery and forming new vessels by enhancing the EPC homing process by reducing oxidative stress in the ischemic hindlimbs of diabetic mice.

FIR therapy for chronic kidney disease

Chronic kidney disease

Chronic kidney disease (CKD) is a progressive renal dysfunction experienced during several months or years⁵² and can be classified into five stages (stages 1 to 5) according to severity. End-stage renal disease (ESRD) is stage 5 CKD and is a severe illness with a poor prognosis for which treatment with dialysis or transplantation may be required.⁵² For patients with ESRD who receive hemodialysis (HD) treatment, native arteriovenous fistulas (AVFs) and prosthetic arteriovenous grafts (AVGs)⁵³ are typically used to obtain the well-functioning vascular access that is critical to sufficient dialysis.⁵⁴

Effects of FIR on CKD

Lin *et al.* showed that long-term FIR exposure increased access flow (Qa), reduced the incidence and relative incidence of AVF malfunction, and improved the unassisted patency of AVFs in HD patients.⁵⁵ Because decreasing vascular Qa is an effective index for estimating thrombosis-related access dysfunctions,⁵⁶ the improvement in the patency of AVFs was likely associated with a higher value of Qa. According to Kipshidze *et al.*,⁵⁷ a non-ablative infrared laser (NIL) restrained neointimal hyperplasia and reduced the proliferation of vascular smooth muscle cells (VSMCs) after percutaneous transluminal coronary angioplasty in cholesterol-fed rabbits for 60 days. Because the growth of VSMCs increases the risk of vascular access stenosis in HD patients,⁵⁸ inhibiting neointimal hyperplasia may be one mechanism through which FIR therapy improves vascular restenosis progression in patients with ESRD.

Furthermore, Lai *et al.* investigated the effect of FIR treatment on HD access maintenance after percutaneous transluminal angioplasties (PTAs) in AVG and AVF populations.⁵⁹ The data showed that a radiated group of patients with AVGs exhibited significantly improved unassisted patency at one year (16.3% vs. 2.1%, $P < 0.05$).⁵⁹ However, in the AVF population, post-PTA FIR radiation therapy non-significantly improved the unassisted patency rate.⁵⁹ The results of clinical trials of FIR radiation therapy were inconsistent with those of Lin *et al.*,⁵⁵ possibly because most patients examined by Lin *et al.* received no PTA treatment.⁵⁵ Overall, because of the improvement in unassisted patency, FIR radiation therapy may benefit PTA-treated AVG and AVF patients who are high-functioning or have not received repeated PTA.

The failure of an AVF to mature is a critical pathologic reason for the malfunction of newly created AVFs in people at advanced stages of CKD.⁶⁰ Lin *et al.* reported that three months of FIR treatment can enhance the rate of AVF maturation significantly (90% vs. 76%, $P < 0.05$).⁶¹ In addition, they demonstrated that FIR stimulation provided substantial benefits of increasing Qa and the rates of AVF unassisted patency and clinical maturation as well as lowering AVF malfunction within one year compared with controls.⁶¹ These results were identical to those of their previous study.⁵⁵ Endothelial dysfunction associated with AVF stenosis may lead to AVF maturation failure in HD patients.⁵⁸ In summary, FIR benefitted HD patients by promoting endothelial function in both animal^{3,7,24} and clinical studies.

FIR therapy for ischemia

Ischemia

Ischemia that triggers the unavailability of oxygen and glucose to tissues is generally ascribed to blood vessel problems, resultant damage, or tissue dysfunction. If not treated immediately, ischemia may aggravate rapidly to tissue necrosis and gangrene within several hours, potentially leading to paralysis.⁶²

Effects of FIR on ischemia

A previous study determined that FIR radiation provides a strong antiinflammatory benefit to the vascular endothelium by inducing heme oxygenase-1 (HO-1) expression.⁶³ HO-1 is a rate-limiting enzyme in heme oxidation of biliverdin and carbon monoxide.⁶⁴ Biliverdin can be further catalyzed to a potent antioxidant bilirubin,⁶⁵ whereas carbon monoxide, similar to NO, exhibited effects of vasodilation and modulating intracellular cGMP levels in one study.⁶⁶ Thus, FIR probably plays a crucial role in increasing cGMP signaling. HO-1 was shown to prevent testis injury in models of hypoxic preconditioning.⁶⁷ Tu *et al.* investigated the effect of FIR postconditioning on ischemia/reperfusion (I/R) injury in rat testes.⁶⁸ The results indicated that HO-1 protein in the testes was overexpressed in a group of rats with 2 h-ischemia I/R injury treated with FIR ray therapy for 30 min compared with untreated and heat light groups.⁶⁸ In addition, administering an HO-1 inhibitor abolished the effect of FIR treatment.⁶⁸ Furthermore, FIR therapy drastically reduced apoptosis and alleviated injury of testis tissue,⁶⁸ suggesting that HO-1 is crucial in FIR postconditioning for protecting rat testis from I/R injury.

In a mouse model of an ischemic hindlimb, Akasaki *et al.* reported that five weeks of FIR sauna therapy markedly upregulated blood flow, capillary density, eNOS expression, and NO production compared with those of controls.⁷ However, administering L-NAME suppressed the effects induced by FIR stimulation.⁷

FIR alleviated tissue ischemia in animal^{3,7,68} and clinical studies.⁶⁹ Tei *et al.* reported that long-term sauna therapy reduced pain scores, increased blood flow, and promoted angiogenesis,⁶⁹ but was ineffective in eNOS-deficient mice. In addition, exercise tolerance was upregulated.⁶⁹

The induction of NO by eNOS is essential for regulating angiogenesis,⁷⁰ and this process can be elicited by vascular endothelial growth factor.⁷¹⁻⁷³ In summary, eNOS is a critical regulator for angiogenesis in repeated FIR sauna therapy. In addition, both eNOS and exercise can increase the mobilization of EPCs,^{51,69} which is vital to vasculogenesis.⁴⁸ Thus, FIR may be a novel innovative therapy for treating ischemic areas.

Successful revascularization of an ischemic region necessitates new blood vessel growth, stabilization, and maturation,^{74,75} which are critical for reducing cell death and increasing the blood supply to damaged areas.⁷⁶ Because of the importance of pericytes in maintaining newly generated microvessels during angiogenesis, pericyte deficiency leads to endothelial cell apoptosis and destabilization of the microvasculature.⁷⁷ Thus, pericyte recruitment likely plays a key role in vascular remodeling in cortical tissues after ischemic stroke. Furthermore, a recent study reported that pericyte relaxation increased blood flow *in vivo*.⁷⁸ Because FIR rays enhance blood flow and improve ischemic areas, although the exact mechanism has not been elucidated, we speculate that FIR rays positively affect pericytes after ischemia.

FIR therapy for other diseases

FIR therapy is effective in relieving pain in patients with chronic pain,⁷⁹ chronic fatigue syndrome,⁸⁰ and




Figure 1 Effects of far-infrared therapy. Far-infrared (FIR) rays enable multiple energy transfer as deep as 2–3 cm into subcutaneous tissue without irritating or overheating the skin and then accelerate blood flow, leading to an increase in shear stress, followed by an increase in endothelial nitric oxide synthase activity and nitric oxide production. Moreover, FIR or shear stress can regulate the expression of some circulating miRNAs in endothelial cells. Consequently, FIR therapy improves the symptoms of chronic diseases (e.g. cardiovascular disease, diabetes mellitus, and chronic kidney disease). (A color version of this figure is available in the online journal.)

fibromyalgia.^{81,82} FIR benefitted trained runners who suffered from muscle damage⁸³ and patients who experienced persistent and progressively increasing phantom limb pain after amputation.⁸⁴ Furthermore, FIR stimulation alleviated depression in patients with insomnia by increasing serotonin and reducing malondialdehyde levels.⁸⁵ However, a case of pseudolymphoma occurring in a blue-green tattoo was thought to be related to FIR light exposure and induced sweating.⁸⁶ These effects on living organisms exposed to FIR rays are poorly understood; therefore, further study is required.

Conclusion and perspectives

As a potential complementary therapy, FIR radiation had both thermal and non-thermal effects. The thermal effect of FIR therapy could increase blood flow and vasodilation by heating the tissue (hyperthermia), similar to ordinary thermal therapy composed of heat pads or hot water.⁸⁷ In addition, FIR treatment with low levels of delivered energy (non-thermal effect) also had biological activities.^{88,89} A study of patients receiving HD treatment had shown decreases in stress and fatigue levels by FIR stimulation

rather than thermal treatment (heat pads), which was probably attributed to the non-thermal effect.¹⁰ An explanation of non-thermal effect of such low energy levels was that nanoscopic water layers got disturbed by low irradiances, leading to the change of cellular membrane structure, then made the therapeutic effects.⁸⁷

Since FIR therapy was frequently applied in the medical field, numerous investigators have attempted to determine the effects of these novel FIR rays on biological systems. FIR radiation has multiple properties; thus, no direct interrelationships among the properties could be identified. Possible explanations include reduction in oxidative stress, improvement in endothelial function, and inhibition of neointimal hyperplasia. Regarding the effect of FIR treatment on oxidative stress downregulation, Masuda *et al.* showed that FIR therapy reduced oxidative stress in patients with coronary risk factors.²⁸ In addition, a decrease in oxidative stress was observed in DM patients who received FIR therapy.^{41,48} Regarding the effect on endothelial function, an intervention group exposed to FIR rays exhibited quicker amelioration of endothelial function than did non-exposed controls in both CVD¹⁶ and CKD populations.⁶¹ Regarding the third mechanism, Kipshidze *et al.* demonstrated that NIL inhibited neointimal hyperplasia.⁵⁷

Furthermore, FIR rays have been applied in treating various chronic diseases, such as hypertension, heart failure, and vascular endothelial dysfunction, which are associated with the depletion of tetrahydrobiopterin (BH4), a critical cofactor for NO synthases.^{90,91} FIR therapy improves blood flow in heated surface areas, causing an increase in vascular shear stress and enhancement of the activity of GTP cyclohydrolase I, which benefits BH4 synthesis.^{92,93} Thus, the increased availability of BH4 may provide key insight into the underlying mechanisms of sauna therapy. A recent study demonstrated that capillaries control blood flow primarily related to active pericyte relaxation.⁷⁸ In addition, pericyte death in rigor results in a permanent decrease in blood flow in capillaries and damages neurons after stroke.^{94–96} These mechanisms resemble FIR in improving capillary dilation and blood flow and may reflect the promotion of stroke recovery by FIR stimulation. In other words, FIR therapy may alleviate stroke by inhibiting pericyte death.

Except for the aforementioned mechanisms, the eNOS and NO-increasing activity of FIR radiation treatment may be recognized as a possible common background (Figure 1).⁹⁷ An increase in blood flow induced by FIR treatment increases shear stress, which is a crucial determinant of endothelial function and phenotype in atherosclerosis. Furthermore, previous evidence has shown that shear stress regulated the expression of miRNAs in endothelial cells, and miRNAs influence endothelial biology by reducing apoptosis and activating the NO pathway.³⁴ Therefore, FIR therapy is a potential therapeutic method for treating CVD because it increases shear stress by regulating the expression of miRNA. Overall, FIR ray treatment accelerates peripheral blood flow, leading to an increase in shear stress; consequently, the miRNA levels are elevated, followed by an increase in eNOS and NO production.

The expression of NOS activity and miRNA has a circadian rhythm and is closely associated with control mechanisms governing circadian expression. Ayers *et al.* reported that NOS activity in the kidneys of mice exhibited a clear circadian variation. The highest level occurred during the dark period and the lowest level occurred during the light period.⁹⁸ In addition, NOS activation mediated the phase-shifting effects of melatonin and 5-hydroxytryptamine on a suprachiasmatic nuclei (SCN) circadian pacemaker in rats.⁹⁹ Moreover, as key regulators of the circadian timing process, miRNA-219 and miRNA-132 levels in SCN exhibited a salient rhythm, the highest level of which occurred during the subjective day.¹⁰⁰ In addition, several miRNAs are involved in the modulation of the peripheral circadian rhythm in mouse livers.^{101,102} Circadian rhythms have been observed in the incidences of cerebrovascular diseases, arterial diseases, and ischemic stroke.^{103,104} These results suggested that the diurnal variation of NOS and miRNAs may be related with that of the onset of some chronic diseases. Therefore, FIR rays may have striking therapeutic effects on medical treatments on the basis of a circadian rhythm. However, further research considering objective parameters and sufficient sample sizes must be conducted in animal models and clinical applications to completely reveal the functional effect of circadian rhythms on FIR rays.

Author contributions: LZ provided ideas and research directions; SS wrote the sections on FIR therapy for CVD, FIR therapy for DM, and FIR therapy for CKD; XW wrote the sections on FIR therapy for ischemia and FIR therapy for other diseases; and JYC provided program support.

ACKNOWLEDGMENTS

We thank Professor Jian Liu for the valuable comments. This study was supported by the specialized Research Fund for the Doctoral Program of Higher Education (20120111110024), the Fundamental Research Funds for the Central Universities (2012HGCX0003, 2013HGQC0045, JZ2014HGBZ0050), the National Key Technologies R&D Programme (2012BAD07B01), and the Funds for Huangshan Professorship of Hefei University of Technology.

REFERENCES

1. Toyokawa H, Matsui Y, Uhara J, Tsuchiya H, Teshima S, Naknishi H, Hon A, Kwon, Azuma Y, Nagaoka T, Ogawa T, Kamiyama Y. Promotive effects of far-infrared ray on full-thickness skin wound healing in rats. *Exp Biol Med (Maywood)* 2003;**228**:724–9
2. Hartel M, Hoffmann G, Wente MN, Martignoni ME, Buchler MW, Friess H. Randomized clinical trial of the influence of local water-filtered infrared A irradiation on wound healing after abdominal surgery. *Br J Surg* 2006;**93**:952–60
3. Yu SY, Chiu JH, Yang SD, Hsu YC, Lui WY, Wu CW. Biological effect of far-infrared therapy on increasing skin microcirculation in rats. *Photodermatol Photoimmunol Photomed* 2006;**22**:78–86
4. Tei C. Waon therapy: soothing warmth therapy. *J Cardiol* 2007;**49**:301–4
5. Bauer BA. Do infrared saunas have any health benefits? Available at: <http://www.bayareahospital.org/Article.aspx?ref=AN02154> (accessed 6 February 2015)

6. Tei C, Horikiri Y, Park J-C, Jeong J-W, Chang K-S, Toyama Y, Tanaka N. Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. *Circulation* 1995;**91**:2582-90
7. Akasaki Y, Miyata M, Eto H, Shirasawa T, Hamada N, Ileda Y, Brio S, Otsuji Y, Tei C. Repeated thermal therapy up-regulates endothelial nitric oxide synthase and augments angiogenesis in a mouse model of hindlimb ischemia. *Circ J* 2006;**70**:463-70
8. Ise N, Katsuura T, Kikuchi Y, Miwa E. Effect of far-infrared radiation on forearm skin blood flow. *Ann Physiol Anthropol* 1987;**6**:31
9. Kihara T, Biro S, Imamura M, Yoshijuku S, Takasaki K, Ikeda Y, Otsuji Y, Minagoe S, Toyama Y, Tei C. Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure. *J Am Coll Cardiol* 2002;**39**:754-9
10. Su LH, Wu KD, Lee LS, Wang H, Liu CF. Effects of far infrared acupoint stimulation on autonomic activity and quality of life in hemodialysis patients. *Am J Chin Med* 2009;**37**:215-26
11. Oosterveld FG, Rasker JJ, Floors M, Rasker JJ, Floors M, Landkroon R, van Rennes B, Zwijnenberg J, van de Laar MAFH, Koel GJ. Infrared sauna in patients with rheumatoid arthritis and ankylosing spondylitis. *Clin Rheumatol* 2009;**28**:29-34
12. Ryotokuji K, Ishimaru K, Kihara K, Namiki Y, Hozumi N. Effect of pinpoint plantar long-wavelength infrared light irradiation on subcutaneous temperature and stress markers. *Laser Ther* 2013;**22**:93
13. Matsumoto S, Kawahira K, Etoh S, Ikeda S, Tanaka N. Short-term effects of thermotherapy for spasticity on tibial nerve F-waves in post-stroke patients. *Int J Biometeorol* 2006;**50**:243-50
14. Fuster V, Kelly BB. *Promoting cardiovascular health in the developing world: a critical challenge to achieve global health*. Washington, DC: National Academies Press, 2010
15. Dantas AP, Jimenez-Altayo F, Vila E. Vascular aging: facts and factors. *Front Physiol* 2012;**3**:325
16. Imamura M, Biro S, Kihara T, Yoshifuku S, Takasaki K, Otsuji Y, Minagoe S, Toyama Y, Tei C. Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. *J Am Coll Cardiol* 2001;**38**:1083-8
17. Sobajima M, Nozawa T, Ihori H, Shida T, Ohori T, Suzuki T, Matsuki A, Yasumura S, Inoue H. Repeated sauna therapy improves myocardial perfusion in patients with chronically occluded coronary artery-related ischemia. *Int J Cardiol* 2013;**167**:237-43
18. Ohori T, Nozawa T, Ihori H, Shida T, Sobajima M, Matsuki A, Yasumura S, Inoue H. Effect of repeated sauna treatment on exercise tolerance and endothelial function in patients with chronic heart failure. *Am J Cardiol* 2012;**109**:100-4
19. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. *N Engl J Med* 1990;**323**:22-7
20. Sorensen K, Celermajer D, Georgakopoulos D, Hatcher G, Betteridge D, Deanfield J. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. *Journal of Clinical Investigation* 1994;**93**(1): 50
21. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. *Circulation* 1993;**88**:2510-6
22. Celermajer D, Sorensen K, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield J. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. *Circulation* 1993;**88**:2149-55
23. Anggard E. Nitric oxide: mediator, murderer, and medicine. *Lancet* 1994;**343**:1199-206
24. Ikeda Y, Biro S, Kamogawa Y, Yoshifuku S, Eto H. Repeated sauna therapy increases arterial endothelial nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. *Circ J* 2005;**69**:722-9
25. Park JH, Lee S, Cho DH, Park YM, Kang DH, Jo I. Far-infrared radiation acutely increases nitric oxide production by increasing Ca(2+) mobilization and Ca(2+)/calmodulin-dependent protein kinase II-mediated phosphorylation of endothelial nitric oxide synthase at serine 1179. *Biochem Biophys Res Commun* 2013;**436**:601-6
26. Pall ML. Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects. *J Cell Mol Med* 2013;**17**:958-65
27. Yuill KH, McNeish AJ, Kansui Y, Garland CJ, Dora KA. Nitric oxide suppresses cerebral vasomotion by sGC-independent effects on ryanodine receptors and voltage-gated calcium channels. *J Vasc Res* 2009;**47**:93-107
28. Masuda A, Miyata M, Kihara T, Minagoe S, Tei C. Repeated sauna therapy reduces urinary 8-epi-prostaglandin F(2alpha). *Jpn Heart J* 2004;**45**:297-303
29. Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure. *Cellular interactions in cardiac pathophysiology*. New York: Springer, 1995, pp.77-81
30. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. *Arterioscler Thromb Vasc Biol* 1997;**17**:2309-15
31. Gryglewski R, Palmer R, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. *Nature* 1986;**320**:454-6
32. Malek AM, Zummo S, Alper SL. Modulation by pathophysiological stimuli of the shear stress-induced up-regulation of endothelial nitric oxide synthase expression in endothelial cells. *Neurosurgery* 1999;**45**:334
33. Kuehnbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. *Circ Res* 2007;**101**:59-68
34. Weber M, Baker MB, Moore JP, Searles CD. MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity. *Biochem Biophys Res Commun* 2010;**393**:643-8
35. Ni C-W, Qiu H, Jo H. MicroRNA-663 upregulated by oscillatory shear stress plays a role in inflammatory response of endothelial cells. *Am J Physiol Heart Circ Physiol* 2011;**300**:H1762-9
36. Wang H-W, Huang T-S, Lo H-H, Huang P-H, Lin C-C, Chang S-J, Liao K-H, Tsai C-H, Chan C-H, Tsai C-F, Cheng Y-C, Chiu Y-L, Tsai T-N, Cheng C-C, Cheng S-M. Deficiency of the microRNA-31-microRNA-720 pathway in the plasma and endothelial progenitor cells from patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 2014;**34**:857-69
37. Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F. microRNAs as peripheral blood biomarkers of cardiovascular disease. *Vasc Pharmacol* 2011;**55**:111-8
38. Li C, Pei F, Zhu X, Duan DD, Zeng C. Circulating microRNAs as novel and sensitive biomarkers of acute myocardial infarction. *Clin Biochem* 2012;**45**:727-32
39. Gardner DG, Shoback DM. *Greenspan's basic & clinical endocrinology*. New York: McGraw-Hill Medical, 2007
40. Association AD. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2008;**31**:S55-60
41. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus effects of improved metabolic control and vitamin e supplementation. *Circulation* 1999;**99**:224-9
42. Wright D, Sutherland L. Antioxidant supplementation in the treatment of skeletal muscle insulin resistance: potential mechanisms and clinical relevance. *Appl Physiol Nutr Metab* 2008;**33**:21-31
43. Kawaura A, Tanida N, Kamitani M, Akiyama J, Mizutani M, Tsugawa N, Okano T, Takeda E. The effect of leg hyperthermia using far infrared rays in bedridden subjects with type 2 diabetes mellitus. *Acta Med Okayama* 2010;**64**:143-7
44. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase association with endothelial dysfunction and clinical risk factors. *Circ Res* 2000;**86**:e85-90
45. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. *Circulation* 2001;**104**:342-5
46. Roy MS, Roy A, Brown S. Increased urinary-free cortisol outputs in diabetic patients. *J Diabetes Complications* 1998;**12**:24-7

47. Ryotokuji K, Ishimaru K, Kihara K, Namiki Y, Hozumi N. Preliminary results of pinpoint plantar long-wavelength infrared light irradiation on blood glucose, insulin and stress hormones in patients with type 2 diabetes mellitus. *Laser Ther* 2013;**22**:209-14
48. Huang PH, Chen JW, Lin CP, Chen YH, Chen YH, Wang CH, Leu HB, Lin SJ. Far infra-red therapy promotes ischemia-induced angiogenesis in diabetic mice and restores high glucose-suppressed endothelial progenitor cell functions. *Cardiovasc Diabetol* 2012;**11**:99
49. Asahara T, Murohara T, Sullivan A, Silver M, Rien van der Zee, Li T, Witzensbichler B, Schatteman G, Isner J-M. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;**275**:964-6
50. Chen Y-H, Lin S-J, Lin F-Y, Wu T-C, Tsao C-R, Huang P-H, Liu P-L, Chen Y-L, Chen J-W. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. *Diabetes* 2007;**56**:1559-68
51. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. *Nat Med* 2003;**9**:1370-6
52. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med* 2003;**139**:137-47
53. Maya ID, Oser R, Saddekni S, Barker J, Allon M. Vascular access stenosis: comparison of arteriovenous grafts and fistulas. *Am J Kidney Dis* 2004;**44**:859-65
54. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. *J Am Soc Nephrol* 1996;**7**:523-35
55. Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. *J Am Soc Nephrol* 2007;**18**:985-92
56. Lin C-C, Chang C-F, Chiou H-J, Sun Y-C, Chiang S-S, Lin M-W, Lee P-C, Yang W-C. Variable pump flow-based Doppler ultrasound method: a novel approach to the measurement of access flow in hemodialysis patients. *J Am Soc Nephrol* 2005;**16**:229-36
57. Kipshidze N, Nikolaychik V, Muckerheidi M, Keelan MH, Chekanov V, Maternowski M, Chawla P, Hernandez I, Iyer S, Dangas G, Sahota H, Leon MB, Roubin G, Moses JW. Effect of short pulsed nonablative infrared laser irradiation on vascular cells in vitro and neointimal hyperplasia in a rabbit balloon injury model. *Circulation* 2001;**104**:1850-5
58. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. *J Am Soc Nephrol* 2006;**17**:1112-7
59. Lai CC, Fang HC, Mar GY, Liou JC, Tseng CJ, Liu CP. Post-angioplasty far infrared radiation therapy improves 1-year angioplasty-free hemodialysis access patency of recurrent obstructive lesions. *Eur J Vasc Endovasc Surg* 2013;**46**:726-32
60. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb H, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. *JAMA* 2008;**299**:2164-71
61. Lin C-C, Yang W-C, Chen M-C, Liu W-S, Yang C-Y, Lee P-C. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. *Am J Kidney Dis* 2013;**62**:304-11
62. Lewis SL, Dirksen SR, Heitkemper MM, Bucher L. *Medical-surgical nursing: assessment and management of clinical problems, single volume*. St. Louis, MO: Elsevier Health Sciences, 2013
63. Lin CC, Liu XM, Peyton K, Wang H, Yang WC, Lin SJ, Durante W. Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. *Arterioscler Thromb Vasc Biol* 2008;**28**:739-45
64. Choi A, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. *Am J Respir Cell Mol Biol* 1996;**15**:9-19
65. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. *Proc Natl Acad Sci U S A* 1987;**84**:5918-22
66. Morita T, Perrella MA, Lee M-E, Kourembanas S. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. *Proc Natl Acad Sci* 1995;**92**:1475-9
67. Tu Y-P, Chuang S-J, Chen S-C, Liu Y-H, Chen C-F, Hour T-C. Simvastatin induces the expression of hemeoxygenase-1 against ischemia-reperfusion injury on the testes in rats. *Toxicol Lett* 2011;**207**:242-50
68. Tu YP, Chen SC, Liu YH, Chen CF, Hour TC. Postconditioning with far-infrared irradiation increases heme oxygenase-1 expression and protects against ischemia/reperfusion injury in rat testis. *Life Sci* 2013;**92**:35-41
69. Tei C, Shinsato T, Miyata M, Kihara T, Hamasaki S. Waon therapy improves peripheral arterial disease. *J Am Coll Cardiol* 2007;**50**:2169-71
70. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. *Circulation* 2002;**105**:2133-5
71. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. *J Clin Invest* 1997;**99**:2625
72. Hsu YH, Chen YC, Chen TH, Sue YM, Cheng TH, Chen CH. Far-infrared therapy induces the nuclear translocation of PLZF which inhibits VEGF-induced proliferation in human umbilical vein endothelial cells. *PLoS one* 2012;**7**:e30674
73. Hwang S, Lee D-H, Lee I-K, Park YM, Jo I. Far-infrared radiation inhibits proliferation, migration, and angiogenesis of human umbilical vein endothelial cells by suppressing secretory clusterin levels. *Cancer Lett* 2014;**346**:74-83
74. Balabanov R, Washington R, Wagnerova J, Dore-Duffy P. CNS microvascular pericytes express macrophage-like function, cell surface integrin α M, and macrophage marker ED-2. *Microvasc Res* 1996;**52**:127-42
75. Díaz-Flores L, Gutiérrez R, Varela H. Angiogenesis: an update. *Histol Histopathol* 1994;**9**:807-43
76. Hayashi T, Noshita N, Sugawara T, Chan PH. Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. *J Cereb Blood Flow Metab* 2003;**23**:166-80
77. Kokovay E, Li L, Cunningham LA. Angiogenic recruitment of pericytes from bone marrow after stroke. *J Cereb Blood Flow Metab* 2006;**26**:545-55
78. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, O'Farrell FM, Buchan AM, Lauritzen M, Attwell D. Capillary pericytes regulate cerebral blood flow in health and disease. *Nature* 2014; **508**:55-60
79. Masuda A, Koga Y, Hattanmaru M, Minagoe S, Tei C. The effects of repeated thermal therapy for patients with chronic pain. *Psychother Psychosom* 2005;**74**:288-94
80. Masuda A, Kihara T, Fukudome T, Shinsato T, Minagoe S, Tei C. The effects of repeated thermal therapy for two patients with chronic fatigue syndrome. *J Psychosom Res* 2005;**58**:383-7
81. Matsushita K, Masuda A, Tei C. Efficacy of Waon therapy for fibromyalgia. *Intern Med* 2008;**47**:1473-6
82. Matsumoto S, Shimodozono M, Etoh S, Miyata R, Kawahira K. Effects of thermal therapy combining sauna therapy and underwater exercise in patients with fibromyalgia. *Complement Ther Clin Pract* 2011;**17**:162-6
83. Hausswirth C, Louis J, Bieuzen F, Pournot H, Fournier J, Filliard J-R, Brisswalter J. Effects of whole-body cryotherapy vs. far-infrared vs. passive modalities on recovery from exercise-induced muscle damage in highly-trained runners. *PLoS one* 2011;**6**:e27749
84. Huang CY, Yang RS, Kuo TS, Hsu KH. Phantom limb pain treated by far infrared ray. *Conf Proc Annu Int Conf IEEE Eng Med Biol Soc* 2009;**2009**:1589-91
85. Chang Y, Liu YP, Liu CF. The effect on serotonin and MDA levels in depressed patients with insomnia when far-infrared rays are applied to acupoints. *Am J Chin Med* 2009;**37**:837-42
86. Chiang C, Romero L. Cutaneous lymphoid hyperplasia (pseudolymphoma) in a tattoo after far infrared light. *Dermatol Surg* 2009;**35**:1434-8
87. Vatanserver F, Hamblin MR. Far infrared radiation (FIR): Its biological effects and medical applications. *Photonics Lasers Med* 2012;**1**:255-66

88. Inoué S, Kabaya M. Biological activities caused by far-infrared radiation. *Int J Biometeorol* 1989;**33**:145–50
89. Chou K-S, Lu Y-C. The application of nanosized silver colloids in far infrared low-emissive coating. *Thin Solid Films* 2007;**515**:7217–21
90. Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, Jones DP, Hooper C, Taylor WR, Harrison D, Quyyumi AA. Tetrahydrobiopterin: a novel antihypertensive therapy. *J Hum Hypertens* 2008;**22**:401–7
91. Antoniadis C, Shirodaria C, Crabtree M, Rinze R, Alp N, Cunningham C, Diesch J, Tousoulis D, Stefanadis C, Lesson P, Ratnatunga C, Pilli R, Channon KM. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. *Circulation* 2007;**116**:2851–9
92. Pall ML. Do sauna therapy and exercise act by raising the availability of tetrahydrobiopterin? *Med Hypotheses* 2009;**73**:610–13
93. Audhya T, Pall ML, Green JA. A study of sauna therapy in myalgic encephalomyelitis/chronic fatigue syndrome patients shows sauna action via raised tetrahydrobiopterin and confirms three predictions of the NO/ONOO-cycle. *Townsend Lett* 2013;**364**:60–64
94. Hauck EF, Apostel S, Hoffmann JF, Heimann A, Kempfski O. Capillary flow and diameter changes during reperfusion after global cerebral ischemia studied by intravital video microscopy. *J Cereb Blood Flow Metab* 2004;**24**:383–91
95. Leffler CW, Beasley DG, Busija DW. Cerebral ischemia alters cerebral microvascular reactivity in newborn pigs. *Am J Physiol Heart Circ Physiol* 1989;**257**:H266–71
96. Baird A, Donnan G, Austin M, Fitt G, Davis S, McKay W. Reperfusion after thrombolytic therapy in ischemic stroke measured by single-photon emission computed tomography. *Stroke* 1994;**25**:79–85
97. Leung T-K, Lee C-M, Lin M-Y, Ho Y-S, Chen C-S, Wu C-H, Lin Y-S. Far infrared ray irradiation induces intracellular generation of nitric oxide in breast cancer cells. *J Med Biol Eng* 2009;**29**:15–8
98. Ayers NA, Kapás L, Krueger JM. Circadian variation of nitric oxide synthase activity and cytosolic protein levels in rat brain. *Brain Res* 1996;**707**:127–30
99. Starkey SJ. Melatonin and 5-hydroxytryptamine phase-advance the rat circadian clock by activation of nitric oxide synthesis. *Neurosci Lett* 1996;**211**:199–202
100. Cheng H-YM, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, Nakazawa T, Shimizu K, Okamura H, Impey S, Obrietan K. microRNA modulation of circadian-clock period and entrainment. *Neuron* 2007;**54**:813–29
101. Na Y-J, Sung JH, Lee SC, Lee YJ, Choi YJ, Park WY, Shin HS, Kim JH. Comprehensive analysis of microRNA-mRNA co-expression in circadian rhythm. *Exp Mol Med* 2009;**41**:638–47
102. Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, Ruskeepää AL, Oresic M, Esau CC, Zdobnov EM, Schibler U. Integration of microRNA miR-122 in hepatic circadian gene expression. *Genes Dev* 2009;**23**:1313–26
103. Quyyumi AA. Circadian rhythms in cardiovascular disease. *Am Heart J* 1990;**120**:726–33
104. Shaw E, Tofler GH. Circadian rhythm and cardiovascular disease. *Curr Atheroscler Rep* 2009;**11**:289–95

(Received June 22, 2014, Accepted December 31, 2014)